Abstract
Superselective adrenal arterial embolization (SAAE) appears to be beneficial in primary aldosteronism (PA) patients with lateralized aldosterone secretion (unilateral PA). As confirmed by adrenal vein sampling (AVS), nearly 40% of PA patients would be PA without lateralized aldosterone secretion (bilateral PA). We aimed to investigate the efficacy and safety of SAAE on bilateral PA. We identified 171 bilateral PA patients from 503 PA patients who completed AVS. Thirty-eight bilateral PA patients received SAAE, and 31 completed a median 12-month clinical follow-up. The blood pressure and biochemical improvements of these patients were carefully analyzed. 34% of patients were identified as bilateral PA. Plasma aldosterone concentration, plasma renin activity, and aldosterone/renin ratio (ARR) were significantly improved 24-h after SAAE. SAAE was associated with 38.7% and 58.6% of complete/partial clinical and biochemical success within a median 12-month follow-up. A significant reduction in left ventricular hypertrophy was shown in patients who obtained complete biochemical success compared with partial/absent biochemical success. SAAE was associated with a more apparent nighttime blood pressure reduction than daytime blood pressure reduction in patients with complete biochemical success. No major adverse safety events related to SAAE were reported during the intraoperative, postoperative, and follow-up periods. SAAE was associated with blood pressure and biochemical improvements in part of bilateral PA and appeared safe. The biochemistry success was accompanied by improved cardiac remodeling and a more prominent decrease in nocturnal blood pressure. This study was part of a trial registered with the Chinese Clinical Trial Registry, number ChiCTR2100047689.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Rossi GP. Surgically correctable hypertension caused by primary aldosteronism. Best Pr Res Clin Endocrinol Metab. 2006;20:385–400.
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889–916.
Lechner B, Lechner K, Heinrich D, Adolf C, Holler F, Schneider H, et al. THERAPY OF ENDOCRINE DISEASE: Medical treatment of primary aldosteronism. Eur J Endocrinol. 2019;181:R147–R153.
Hundemer GL, Vaidya A. MANAGEMENT OF ENDOCRINE DISEASE: The role of surgical adrenalectomy in primary aldosteronism. Eur J Endocrinol. 2020;183:R185–R196.
Moran W, Goetz FC, Melby J, Zimmermann B, Kennedy BJ. Primary hyperaldosteronism without adrenal tumor. Am J Med. 1960;28:638–47.
George JM, Wright L, Bell NH, Bartter FC. The syndrome of primary aldosteronism. Am J Med. 1970;48:343–56.
Weinberger MH. Primary Aldosteronism: Diagnosis, Localization, and Treatment. Ann Intern Med. 1979;90:386.
Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of Unilateral Adrenalectomy in Bilateral Primary Aldosteronism: A 22-Year Single Center Experience. J Clin Endocrinol Metab. 2009;94:2437–45.
Inoue H, Nakajo M, Miyazono N, Nishida H, Ueno K, Hokotate H. Transcatheter arterial ablation of aldosteronomas with high-concentration ethanol: preliminary and long-term results. Am J Roentgenol. 1997;168:1241–5.
Hokotate H, Inoue H, Baba Y, Tsuchimochi S, Nakajo M. Aldosteronomas: Experience with Superselective Adrenal Arterial Embolization in 33 Cases. Radiology. 2003;227:401–6.
Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F, et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof‐of‐principle trial. J Clin Hypertens. 2020;22:1618–26.
Dong H, Zou Y, He J, Deng Y, Chen Y, Song L, et al. Superselective adrenal arterial embolization for idiopathic hyperaldosteronism: 12‐month results from a proof‐of‐principle trial. Catheter Cardiovasc Inter. 2021;97:976–81.
Zhao Z, Liu X, Zhang H, Li Q, He H, Yan Z, et al. Catheter-Based Adrenal Ablation Remits Primary Aldosteronism: A Randomized Medication-Controlled Trial. Circulation. 2021;144:580–2.
Rossi GP, Auchus RJ, Brown M, Lenders JWM, Naruse M, Plouin PF, et al. An Expert Consensus Statement on Use of Adrenal Vein Sampling for the Subtyping of Primary Aldosteronism. Hypertension. 2014;63:151–60.
Endocrinology branch of Chinese Medical Association. Expert consensus on the diagnosis and treatment of primary aldosteronism (2020). Chin J Endocrinol Metab. 2020;36:727–36.
Cao C, Hu J-X, Dong Y-F, Zhan R, Li P, Su H, et al. Association of Endothelial and Mild Renal Dysfunction With the Severity of Left Ventricular Hypertrophy in Hypertensive Patients. Am J Hypertens. 2016;29:501–8.
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.
Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol. 2017;5:689–99.
Kempers MJE. Systematic Review: Diagnostic Procedures to Differentiate Unilateral From Bilateral Adrenal Abnormality in Primary Aldosteronism. Ann Intern Med. 2009;151:329.
Vorselaars WMCM, Nell S, Postma EL, Zarnegar R, Drake FT, Duh Q-Y, et al. Clinical Outcomes After Unilateral Adrenalectomy for Primary Aldosteronism. JAMA Surg. 2019;154:e185842.
Rutherford JC, Taylor WL, Stowasser M, Gordon RD. Success of Surgery for Primary Aldosteronism Judged by Residual Autonomous Aldosterone Production. World J Surg. 1998;22:1243–5.
Proye CAG, Mulliez EAR, Carnaille BML, Lecomte-Houcke M, Decoulx M, Wémeau JL, et al. Essential hypertension: First reason for persistent hypertension after unilateral adrenalectomy for primary aldosteronism? Surgery. 1998;124:1128–33.
Takeda M, Yamamoto K, Akasaka H, Rakugi H, Naruse M, Takeda Y, et al. Clinical Characteristics and Postoperative Outcomes of Primary Aldosteronism in the Elderly. J Clin Endocrinol Metab. 2018;103:3620–9.
Aune A, Gerdts E, Kokorina M, Kringeland E, Midtbø H, Løvås K, et al. Persistent cardiac organ damage in surgically and medically treated primary aldosteronism. J Hypertens. 2022;40:1204–11.
Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-Term Control of Arterial Hypertension and Regression of Left Ventricular Hypertrophy With Treatment of Primary Aldosteronism. Hypertension. 2013;62:62–69.
Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long-Term Cardiac Effects of Adrenalectomy or Mineralocorticoid Antagonists in Patients With Primary Aldosteronism. Hypertension. 2007;50:911–8.
Pan C-T, Wu X-M, Tsai C-H, Chang Y-Y, Chen Z-W, Chang C-C, et al. Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism. Front Endocrinol. 2021;12:646097.
Wu Q, Hong M, Xu J, Tang X, Zhu L, Gao P, et al. Diurnal blood pressure pattern and cardiac damage in hypertensive patients with primary aldosteronism. Endocrine. 2021;72:835–43.
Hui D, Xiongjing J, Ting G, Tuo L, Meng P, Haiying W, et al. Management of primary aldosteronism by percutaneous super-selective adrenal artery embolization. Zhonghua Gaoxueya Zazhi. 2013;21:536–41.
Yang M-H, Tyan Y-S, Huang Y-H, Wang S-C, Chen S-L. Comparison of radiofrequency ablation versus laparoscopic adrenalectomy for benign aldosterone-producing adenoma. Radio Med. 2016;121:811–9.
Liu SY, Chu CM, Kong AP, Wong SK, Chiu PW, Chow FC, et al. Radiofrequency ablation compared with laparoscopic adrenalectomy for aldosterone-producing adenoma. Brit J Surg. 2016;103:1476–148.
Bouhanick B, Delchier MC, Lagarde S, Boulestreau R, Conil C, Gosse P, et al. Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study. J Hypertens. 2021;39:759–65.
Sarwar A, Brook OR, Vaidya A, Sacks AC, Sacks BA, Goldberg SN, et al. Clinical Outcomes following Percutaneous Radiofrequency Ablation of Unilateral Aldosterone-Producing Adenoma: Comparison with Adrenalectomy. J Vasc Inter Radio. 2016;27:961–7.
Zarnegar R, Young WF, Lee J, Sweet MP, Kebebew E, Farley DR, et al. The Aldosteronoma Resolution Score: Predicting Complete Resolution of Hypertension After Adrenalectomy for Aldosteronoma. Ann Surg. 2008;247:511–8.
Rossi GP, Bolognesi M, Rizzoni D, Seccia TM, Piva A, Porteri E, et al. Vascular Remodeling and Duration of Hypertension Predict Outcome of Adrenalectomy in Primary Aldosteronism Patients. Hypertension. 2008;51:1366–71.
Funding
The present study was funded by the National Natural Science Foundation of China (81960088).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Qiu, J., Li, N., Xiong, HL. et al. Superselective adrenal arterial embolization for primary aldosteronism without lateralized aldosterone secretion: an efficacy and safety, proof-of-principle study. Hypertens Res 46, 1297–1310 (2023). https://doi.org/10.1038/s41440-023-01236-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-023-01236-8
Keywords
This article is cited by
-
The impact of superselective adrenal artery embolization on renal function in patients with primary aldosteronism: a prospective cohort study
Hypertension Research (2024)
-
The application of superselective adrenal artery embolization in primary aldosteronism: evaluation, challenges, and response to Mr. Cabrelle and his team
Hypertension Research (2024)
-
Accumulating evidence suggests the potential of selective adrenal artery embolization as a standard treatment for primary aldosteronism
Hypertension Research (2024)